Business
Medical Marijuana, Inc. CEO Featured on Seeking Alpha’s CEO Interviews Podcast
Medical Marijuana, Inc. CEO Featured on Seeking Alpha’s CEO Interviews Podcast.
About this update from Medical Marijuana, Inc.
[{"type":"text","content":"\n SAN DIEGO, Nov. 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its CEO Blake Schroeder was featured on an episode of Seeking Alpha’s CEO Interviews podcast discussing the current landscape of cannabis stocks. The November 17, 2021 episode entitled “Making Sense Of Cannabis Stocks” featured a panel of top cannabis industry leaders, including Schroeder, discussing recent pending cannabis legislation and financial news as well as the many challenges and opportunities that currently exist for businesses in the cannabis industry. Schroeder highlighted the many first-mover milestones Medical Marijuana, Inc. has achieved over the years as well as where the Company is headed. He also elaborated on his optimism for the impact of several different legislative moves that could help the cannabis industry see exponential growth within the next few years. “It is an honor to be invited to speak on Seeking Alpha’s podcast and a pleasure to participate in such an insightful discussion with seasoned industry professionals who, like us, are also working tirelessly to ensure free access to cannabis products in the US and around the world,” said Medical Marijuana, Inc. CEO, Blake Schroeder. According to New Frontier Data, the US is projected to reach $51 billion in legal cannabis sales by 2025. In addition, Grand View Research has reported that the global legal marijuana market size is expected to reach $70.6 billion by 2028. About Medical Marijuana, Inc. We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc....